Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Optimizing the Care Pathway for Advanced Epithelioid Sarcoma: Diagnosis, Treatment, and Beyond : Episode 4

Navigating Diagnostic Challenges in Epithelioid Sarcoma: Multidisciplinary Strategies to Optimize Diagnosis

April 25, 2025
By Neeta Somaiah, MD
Edwin Choy, MD, PhD
  • Brian Rubin, MD, PhD

Opinion
Video

Panelists discuss how recognizing the diagnostic challenges of epithelioid sarcoma (ES)—including its histologic overlap with other conditions and the importance of INI1 loss as a key marker—can improve early detection and reduce misdiagnosis of this rare and aggressive tumor.

EP: 1.Epithelioid Sarcoma: Overview and Presentation

EP: 2.Epithelioid Sarcoma: Histological Features and Differential Diagnoses

EP: 3.Confirming Epithelioid Sarcoma: Diagnostic Approach, Imaging, and Molecular Markers

Now Viewing

EP: 4.Navigating Diagnostic Challenges in Epithelioid Sarcoma: Multidisciplinary Strategies to Optimize Diagnosis

Summary for Physicians: Diagnostic Challenges and Pitfalls in ES

Diagnosing ES is often challenging due to its rarity, variable presentation, and histologic overlap with other conditions. Common diagnostic pitfalls include misinterpreting ES as benign lesions such as granulomatous inflammation or reactive processes, especially in the early stages. The tumor’s epithelioid appearance may also lead to misclassification as carcinoma or other soft tissue sarcomas.

Timely diagnosis is complicated by the typically indolent growth of ES, especially in the distal (classic) subtype, which can delay clinical suspicion. The proximal (large cell) subtype can mimic other high-grade sarcomas or poorly differentiated carcinomas due to its more aggressive features and deep-seated location.

ES is frequently misdiagnosed—often initially mistaken for infections, benign cysts, or other sarcoma subtypes. A key diagnostic marker is loss of INI1 (SMARCB1), which should be assessed in cases with ambiguous histology. Awareness of these diagnostic nuances and incorporating molecular testing early in the workup can significantly improve diagnostic accuracy.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
2 experts in this video
2 experts in this video
Related Content
Advertisement

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022
Article

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.


Recap: Recent Research in Multiple Myeloma

Recap: Recent Research in Multiple Myeloma

ONCOLOGY Staff
November 4th 2022
Article

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.


Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff
September 18th 2022
Article

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.


Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

ONCOLOGY Staff
July 17th 2022
Article

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.


Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

ONCOLOGY Staff
July 16th 2022
Article

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.


Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

ONCOLOGY Staff
June 20th 2022
Article

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.

Related Content
Advertisement

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond

ONCOLOGY Staff
November 5th 2022
Article

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.


Recap: Recent Research in Multiple Myeloma

Recap: Recent Research in Multiple Myeloma

ONCOLOGY Staff
November 4th 2022
Article

At an Around the Practice program in Charlotte, NC, experts spoke about the most recent research in multiple myeloma.


Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer

ONCOLOGY Staff
September 18th 2022
Article

Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.


Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

Recap: Mayo Experts Review Treatment Options for Newly Diagnosed Multiple Myeloma

ONCOLOGY Staff
July 17th 2022
Article

Expert panelists review key data from recent meetings on the management of multiple myeloma and consider how these can be applied to clinical practice.


Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases

ONCOLOGY Staff
July 16th 2022
Article

Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.


Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma

ONCOLOGY Staff
June 20th 2022
Article

A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.